Health
IMV Provides Updates On COVID-19 Vaccine Program – BioSpace
Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on its vaccine candidate, DPX-COVID-19, for the prevention of infection caused by the novel coronavirus SARS-COV-2.
We are advancing DPX-COVID-19 on the strength of its novel mechanism of action and potential for rapid scale-up manufacturing. We greatly appreciate…
-
Noosa News23 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Noosa News22 hours agoAfter Hours Gallery Visits, French Dining and Garden Illuminations: Your Guide to the Ultimate Melbourne Culture Fix
-
Business23 hours agoDown 12% this year, should you buy Alphabet stock?
-
General20 hours agoDeath of 86-year-old driver in Karoonda Highway crash prompts push for change